| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_31a179ddd5e18c0a6d1da6db56309db0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d483aa0f120c588daeaa4f9f6e659d8b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_59e05e323cfcee1f7993bc70bda40ffc |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-21
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-34 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-42
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-109 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-21
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 |
| filingDate |
2008-12-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b9f55779db641f0205c2a1504a3e83ef
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_94d8369d8625f850038347a46ac47833
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_285c7377e0d1950beb42c3028bedb4e0 |
| publicationDate |
2009-08-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2009202482-A1 |
| titleOfInvention |
Prevention and Treatment of HCV Infection Employing Antibodies Directed Against Conformational and Linear Epitopes |
| abstract |
Conformational epitopes of the envelope proteins E1 and E2 of the Hepatitis C virus (HCV) have been identified and characterized using a panel of monoclonal antibodies derived from patients infected with HCV. These conserved conformational and linear epitopes of the HCV protein E1 or E2 have been determined to be important in the immune response of humans to HCV and may be particularly important in neutralizing the virus. Based on the identification of these conformational epitopes, vaccines containing peptides and mimotopes with these conformational epitopes intact may be prepared and administered to patients to prevent and/or treat HCV infection. The identification of four distinct groups of monoclonal antibodies with each directed to a particular epitope of E1 or E2 may be used to stratify patients based on their response to HCV and may be used to determine a proper treatment regimen. Pharmaceutical compositions for prevention and treatment of HCV, comprising one or more the monoclonal antibodies, are provided. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8390786-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8390781-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8395752-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8253923-B1 |
| priorityDate |
1998-11-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |